Skip to main content
NFL Biosciences logo

NFL Biosciences — Investor Relations & Filings

Ticker · ALNFL ISIN · FR0014003XT0 LEI · 9695006VJWNTN4UNHA27 PA Professional, scientific and technical activities
Open in API
Filings indexed 184 across all filing types
Latest filing 2026-02-19 Report Publication Anno…
Country FR France
Listing PA ALNFL

About NFL Biosciences

https://www.nflbiosciences.com/

NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead product, NFL-101, is a nicotine-free drug candidate for smoking cessation derived from a protein extract of tobacco leaves. Its development pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences focuses on advancing its products through clinical trials with the goal of licensing them to pharmaceutical companies for commercialization.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Report Publication Announcement Classification · 100% confidence The document is a short press release (under 2,000 characters) that serves solely to announce the company's upcoming financial calendar for the year 2026. It does not contain financial results, audit reports, or other substantive data, but rather informs stakeholders of the dates when future reports will be published. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2026-02-19 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 98% confidence The document is a short press release (under 2,000 characters) from NFL Biosciences announcing their financial calendar for the year 2026. It lists upcoming dates for annual results, the general meeting, and interim results. Since it is an announcement regarding the timing and schedule of future report releases rather than the reports themselves, it falls under the Report Publication Announcement (RPA) category.
2026-02-19 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from NFL Biosciences announcing significant updates to their clinical development strategy, including new efficacy objectives for their drug candidates (NFL-101 and NFL-102), mechanism of action findings, and intellectual property extensions. It is a corporate announcement detailing business and clinical progress, which falls under the category of general regulatory announcements or corporate news updates.
2026-01-26 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release from NFL Biosciences titled 'NFL Biosciences significantly raises its efficacy targets for smoking cessation'. It details updates on clinical development strategies, drug candidates (NFL-101 and NFL-102), mechanism of action research, and intellectual property. It is not a periodic financial report, a transcript, or a governance document. It functions as a corporate announcement regarding business strategy and R&D progress, which falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2026-01-26 English
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Transaction in Own Shares Classification · 100% confidence The document is a press release from NFL Biosciences detailing the semi-annual report of its liquidity contract with Invest Securities for the second half of 2025. It provides specific data on share transactions (purchases and sales) and the remaining balance in the liquidity account. This type of disclosure is a standard regulatory requirement for companies listed on Euronext Growth Paris to report on their share buyback/liquidity programs. Since it is a periodic report of transactions in own shares, it falls under the 'Transaction in Own Shares' category.
2026-01-06 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 93% confidence The document is a press release from NFL Biosciences announcing scientific results regarding their drug candidate NFL-101. It details the characterization of the drug, its regulatory implications, and the potential for a new patent. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As a general corporate announcement regarding business operations and R&D progress, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2025-12-08 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.